Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post on X:
“Chronotherapy in Advanced NSCLC.
Early vs late immunochemotherapy (before vs after 15:00 h) in stage IIIC–IV NSCLC without drivers. PFS: 11.3 vs 5.7 mo HR 0.40 (95% CI 0.29–0.55), P<0.001 OS: 28.0 vs 16.8 mo HR 0.42 (95% CI 0.29–0.60), P<0.001 No excess irAEs. Early dosing ↑ activated CD8+ T cells.”
Title: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
Authors: Zhe Huang, Liang Zeng, Zhaohui Ruan, Qun Zeng, Huan Yan, Wenjuan Jiang, Yi Xiong, Chunhua Zhou, Haiyan Yang, Li Liu, Jiacheng Dai, Nachuan Zou, Shidong Xu, Ya Wang, Zhan Wang, Jun Deng, Xue Chen, Jing Wang, Hua Xiang, Xiaomei Li, Boris Duchemann, Guoqiang Chen, Yang Xia, Tony Mok, Yongchang Zhang
Read the Full Article.
Other article sfeaturing Diego A. Díaz-García on OncoDaily.
